Weight Loss Surgery News Blog

Link: http://www.robertorizzi.com/diabetic-surgery.htm

Obese patients with uncontrolled type 2 diabetes who were treated with an investigational endoscopic duodenal-jejunal bypass liner achieved near normalization of glycemic control in one week, as compared with a sham group. Implantation of the liner was also associated with reductions in fasting blood glucose levels and weight loss.

The EndoBarrier (GI Dynamics) is a non-surgical therapeutic device that is implanted in the gastrointestinal tract through an endoscopic outpatient procedure. It creates a barrier between food and the wall of the small intestine and thereby changes metabolic pathways by controlling how food moves through the digestive system.

In clinical studies conducted to date with the EndoBarrier, patients have experienced immediate resolution of type 2 diabetes while the EndoBarrier is implanted, and continued resolution of their diabetes after the device is removed, as well as the important benefit of weight loss.

Source

Link: http://www.robertorizzi.com/qualification.htm

In gastric bypass surgery, the surgeon basically cut your small intestine in two and then hooks it back up again in such a way that it's much shorter than before. With the first section of your small intestine out of commission, food flows directly from your stomach to the middle of your small intestine. When less intestine is available to absorb food, less food is absorbed.

GI Dynamics, a medical company in Massachusetts, has invented an impermeable intestine liner. It looks like a long clear plastic stocking, and it's simply threaded through the patient's mouth down the stomach to the small intestine, where it lines the upper section (the same part that is bypassed in traditional surgery).

Results of a current clinical trial, released on September 28, 2008, show that patients fitted with an EndoBarrier lost about 30 pounds in 12 weeks, while controls lost only about 10 pounds. Not only that, but EndoBarrier patients with type 2 experienced lower blood sugar levels and/or reduced need for medication. This According to a GI Dynamics press release.

The EndoBarrier is not yet available to the public because it is still in clinical trials.